CF Trading Volume Surges 54.7% to 2.24 Billion, Ranks 391st in Daily Market

On March 25, 2025, CF's trading volume reached 2.24 billion, marking a 54.7% increase from the previous day, placing it 391st in the daily market rankings. CF's stock price fell by 2.34%.

CF Foundation has invested up to $2.3 million in Owlstone Medical to develop a breath test for diagnosing and monitoring Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients. This investment aims to create a less invasive diagnostic tool compared to traditional sputum culture methods, which are challenging for children and adults on CF therapies. The breath test will use Owlstone's volatile organic compound analysis to distinguish P. aeruginosa from other bacterial pathogens, potentially improving outcomes for CF patients.

Owlstone Medical, based in Cambridge, UK, will initially focus on monitoring chronic P. aeruginosa infections, followed by detecting new infections. The company's Breath Biopsy platform, backed by experience from projects with the US Department of Defense and the Gates Foundation, positions it well to advance this technology. Owlstone also has a portfolio of breath biopsy tests in development for early lung cancer detection and liver disease, with assays for small intestinal bacterial overgrowth and carbohydrate malabsorption already on the market in the UK.